Supply Chain's Role in Non-Labor Expense Management (Re-engineering the Health Care Supply Chain: CQO Thought Leader Discussion Series)

AHRMM Webinar Image

 

Price: Member: FREE  |  Non-Member: $49.00

CEC Hours: 1

Order Webinar

  

 

Re-engineering the Health Care Supply Chain: A CQO Thought Leader Discussion Series” is hosted by AHRMM's Cost, Quality and Outcomes (CQO) Movement sponsors. This webinar series focuses on how the health care supply chain will evolve and be more resilient in the post-pandemic environment.

With the potential for increased supply costs due to changes in vendor and inventory strategies and the COVID-19 pandemic, supply chain teams have an opportunity to bring their expertise to deliver savings to non-expense categories. In the third webinar in the CQO Thought Leader Discussion Series, supply chain leaders from Stanford Health Care and Texas Children’s Hospital share their processes and experiences in managing non-labor and non-personnel expenses.

Takeaways include opportunity identification, methodologies and how supply chain professionals can take an active role in managing expense categories beyond the traditional medical/surgical and capital budget line items.

For future webinars in this series, visit the AHRMM Calendar.

 

Panelists:

  • Amanda Chawla, CMRP, MHA, FACHE, Vice President of Supply Chain, Stanford Health Care
  • Eric Swaim, Manager of Strategic Sourcing and Vendor Management, Texas Children's Hospital

 

Sponsored By:

CQO Sponsors

Related Resources

Toolkits/Methodology
Read examples of Green Light Projects illustrating how the performance improvement measures on the Sustainability Roadmap for Hospitals websi
Advisory
An overview of Fiscal Year (FY) 2015 Hospital Value-Based Purchasing (VBP) Program.
Advisory
The Patient Protection and Affordable Care Act of 2010 (ACA) requires the Secretary of Health and Human Services to establish a VBP program t
Advisory
Hospital Compare: CMS Suspends Display of Hospital-Acquired Conditions Data
Letter/Comment
AHRMM comments to the FDA regarding an amendment to the UDI proposed rule to address the UDI implementation time frame required by the 2012 Fo